Nijhawan Pardeep 4

What Happened

• Pardeep Nijhawan, CEO of Edesa Biotech (EDSA), was granted 1,671 restricted share units (RSUs) on 2026-06-01. The award was reported as an acquisition (code A) at $0.00 per share in a Form 4 filing and vested in full upon grant under the Issuer's 2019 Equity Incentive Compensation Plan.

Key Details

• Transaction date: 2026-06-01; transaction type: Award/Grant (A).
• Shares acquired: 1,671 RSUs; reported acquisition price/value: $0.00.
• Filing date / Period of report: 2026-06-01 — filing appears timely (no late-filing flag).
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes: (F1) RSUs vested in full upon grant per the 2019 Equity Incentive Compensation Plan; (F2 & F3) Nijhawan disclaims beneficial ownership of certain shares held by his wholly owned entities and as co-trustee of a family trust, except to the extent of his pecuniary interest.

Context

• This was an equity award (not a market purchase or sale). Awards that vest immediately are compensation events rather than open-market purchases and do not by themselves indicate the insider is increasing or decreasing a market position.
• The filing does not show any simultaneous sale or cashless exercise of these shares.